Publications:

• Barker, C., “An Exploratory Method for Summarizing Concomitant Medication Data – The Mean Cumulative Function”, Pharmaceutical Statistics, Volume 9, Issue 4, pages 331–336, October/December 2010. VIEW
• Barker, C. “The Mean, Median, and Confidence Intervals of the Kaplan-Meier Survival Estimate—Computations and Applications”, The American Statistician (TAS), February 2009, pp. 78-80. VIEW
• RADM Faye G. Abdellah Publication Award for Nursing Research, United States Public Health Service, 2006 for “Effect of long-cycle structure intermittent versus continuous HAART on Quality of Life in Patient in Patients with Chronic HIV infection.”
• Effect of long-cycle structure intermittent versus continuous HAART on Quality of Life in Patient in Patients with Chronic HIV infection. Powers, A., Marden, S., McConnell, R., Leidy, N., Camplbel, C., Soeken, K., Barker, C., Davey, R., Dybul, M. AIDS, vol 20, No 6, pp 837-845.
• “Impact of Nesiritide Use on Hospital Treatment of Acute Decompensated Heart Failure (ADHF): Evidence from US Hospital Database”. Sengupta, N., Barker, C. Mitchell, B. ISPOR 2007. Awarded ISPOR Best Poster Award. VIEW
• “Impact of Nesiritide Use on Hospital Treatment of Acute Decompensated Heart Failure (ADHF): Evidence from US Hospital Database”. Sengupta, N., Barker, C. Mitchell, B. American Society of Health System Pharmacists, 2006.
• Reddy, Rai, Barker, C. Lim, Klein, Patient Benefit From Trastuzumab Plus A Taxane Regardless Of Estrogen Receptor (ER) Status Or Prior Adjuvant Therapy For HER2+ Metastatic Breast Cancer (MBC). ASCO 2004.
• Bernstein D, Kleinman L, Barker C, Revicki DA, Green J Relationship of Health-Related Quality of Life to Treatment Adherence and Sustained Response in Chronic Hepatitis C Patients. Hepatology 2002 Mar; 35:704-708.
• Kleinman L, Zodet M, Hakim Z, Aledort J, Barker C, Chan K, Drupp L, Revicki D Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Quality of Life Research 2000; 9:499-508.
• 1999 Revicki DA, Moyle G, Stellbrink H, Barker C Quality of Life Outcomes of Combination Zalcitabine-Zidovudine, Saquinavir-Zidovudine, and Saquinavir-Zalcitabine-Zidovudine Therapy for HIV-infected Adults with CD4 Cell Counts Between 50 and 350 per Cubic Millimeter. AIDS 1999; 13:851-858.
• How Does Patient Report of Symptom Impact Relate to Clinical Functioning in Chronic Bronchitis? Frank L, Margolis MK, Barker C, Duprat-Lomon , Amiot N, Sagnier P. Poster Session: ISPOR 8th Annual International Meeting - Translating Scientific Advances into Better Patient Care.
• Twelves, C. Boyer, M. Findlay, M. Cassiday, J. Weitzel, C., Barker, C., Osterwalder, B., Jamieson, C., Hieke, K. Xeloda Colorectal Cancer Study Group, “Capecitabine (XelodaTM) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma,” European Journal of Cancer, 37, 597-604.
• Medical Resource Use In A Phase Iii Trial Of Xeloda (Capecitabine) In Previously Untreated Advanced/Metastatic Colorectal Cancer, C. Twelves, E. van Cutsem, K. Hieke, C. Barker, C. Jamieson, J. Hornberger, L. Garrison, B. Osterwalder, A. Thibault European Journal of Cancer, Vol. 35, Suppl. 4, September 99
• Structural Damage Is A Major Driver Of Disability In Rheumatoid Arthritis. Results From A 10-Year Cohort Study. T. Sokka, L. Paimela, P. Hannonen, M. Leirisalo-Repo, K. Hieke, W. Feil, D. Carr, C. Barker Proceedings Of Acr 1999
• Revicki D, Moyle G, Stellbrink H, Barker C. Quality of life outcomes of combination zalcitabine- zidovudine, sauinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 cells/mm3. AIDS 1999; 13:851-858.
• Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Quality of life Research, 2000; 9, 499-508.
• Over 36 Abstracts, Posters Publications and Presentations – available on request.